Marc G. Ghany, MD, MHSc
JAMA Intern Med. 2015;175(2):169-170. doi:10.1001/jamainternmed.2014.4299
Jessica M. Peña, MD, MPH; Sara Aspberg, MD, PhD; Jean MacFadyen, BA; et al.
JAMA Intern Med. 2015;175(2):171-177. doi:10.1001/jamainternmed.2014.6388
This randomized clinical trial found that among men and women with elevated high-sensitivity C-reactive protein levels enrolled in a large trial of rosuvastatin therapy for cardiovascular disease, statin therapy did not reduce the risk of fracture.
Adeel A. Butt, MD, MS; Peng Yan, MS; Vincent Lo Re III, MD, MSCE; et al.
JAMA Intern Med. 2015;175(2):178-185. doi:10.1001/jamainternmed.2014.6502
In this secondary data analysis, Butt et al found that HCV+ persons have a more rapid progression of liver fibrosis and accelerated time to development compared with HCV− controls.
Jean-Pascal Fournier, MD, PhD; Laurent Azoulay, PhD; Hui Yin, MSc; et al.
JAMA Intern Med. 2015;175(2):186-193. doi:10.1001/jamainternmed.2014.6512
This nested case-control analysis found that the initiation of tramadol therapy for noncancer pain is associated with an increased risk of hypoglycemia requiring hospitalization.
Audio Author Interview:
Tramadol and Hospitalization for Hypoglycemia (JAMA Internal Medicine)
Tramadol and Hypoglycemia: One More Thing to Worry About
Lewis S. Nelson, MD; David N. Juurlink, MD, PhD
Less Is More
Prachi Sanghavi, BS; Anupam B. Jena, MD, PhD; Joseph P. Newhouse, PhD; et al.
JAMA Intern Med. 2015;175(2):196-204. doi:10.1001/jamainternmed.2014.5420
This observational cohort study demonstrates that patients with out-of-hospital cardiac arrest who received basic life support had higher survival at hospital discharge and 90 days compared with those who received advanced life support and were less likely to have poor neurological functioning.
Amit N. Vora, MD, MPH; DaJuanicia N. Holmes, MS; Ivan Rokos, MD; et al.
JAMA Intern Med. 2015;175(2):207-215. doi:10.1001/jamainternmed.2014.6573
This US data registry study finds that neither fibrinolysis nor primary percutaneous coronary intervention is being optimally used to achieve guideline-recommended reperfusion targets in patients with ST-segment elevation myocardial infarction. See the Invited Commentary by Claeys.
Jennifer S. Haas, MD, MSc; Jeffrey A. Linder, MD, MPH; Elyse R. Park, PhD, MPH; et al.
JAMA Intern Med. 2015;175(2):218-226. doi:10.1001/jamainternmed.2014.6674
This randomized clinical trial evaluates a proactive tobacco cessation program that addresses sociocontextual mediators of tobacco use for low-socioeconomic-status smokers.
Less Is More
Anupam B. Jena, MD, PhD; Vinay Prasad, MD; Dana P. Goldman, PhD; et al.
JAMA Intern Med. 2015;175(2):237-244. doi:10.1001/jamainternmed.2014.6781
High-risk patients with heart failure and cardiac arrest hospitalized in teaching hospitals had lower 30-day mortality when admitted during dates of national cardiology meetings. High-risk patients with acute myocardial infarction admitted to teaching hospitals during meetings were less likely to receive percutaneous coronary intervention , without any mortality effect.
Less Is More
Kenneth K. Mugwanya, MBChB, MS; Christina Wyatt, MD, MS; Connie Celum, MD, MPH; et al.
JAMA Intern Med. 2015;175(2):246-254. doi:10.1001/jamainternmed.2014.6786
This randomized placebo-controlled trial finds that preexposure prophylaxis with tenofovir disoproxil fumarate in HIV-1–negative adults was not accompanied by a substantial increase in clinically relevant eGFR decline.
Preexposure Prophylaxis: A Path Forward
Mitchell H. Katz, MD
Seth A. Berkowitz, MD, MPH; James B. Meigs, MD, MPH; Darren DeWalt, MD, MPH; et al.
JAMA Intern Med. 2015;175(2):257-265. doi:10.1001/jamainternmed.2014.6888
This cross-sectional study finds that material need insecurities were common among patients with diabetes mellitus and had varying but generally adverse associations with control of diabetes mellitus and the use of health care resources.
Peter Hajek, PhD; Hayden McRobbie, MB, ChB, PhD; Katherine Myers Smith, DPsych; et al.
JAMA Intern Med. 2015;175(2):266-271. doi:10.1001/jamainternmed.2014.6916
This double-blind randomized placebo-controlled trial finds that increasing varenicline dose in smokers with low response to the drug had no significant effect on tobacco withdrawal symptoms or smoking cessation. See the Invited Commentary by Rigotti.